Brugada syndrome is a rare cardiac arrhythmia characterized by 
electrocardiographic right bundle branch block and persistent ST-segment 
elevation in the right precordial leads. It is associated with ventricular 
fibrillation and a high risk for sudden cardiac death, predominantly in younger 
males with structurally normal hearts. Patients can remain asymptomatic, and 
electrocardiographic patterns can occur both spontaneously or after 
pharmacological induction. So far, several pathogenic genes have been identified 
as associated with the disease, but SCN5A is the most prevalent one. Two 
consensus reports to define the diagnostic criteria, risk stratification, and 
management of patients have been published in the last few years. This brief 
review focuses on the recent clinical diagnosis, genetic basis, and advances in 
pharmacological treatment of Brugada syndrome.